Haloperidol for the treatment of nausea and vomiting in palliative care patients

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2015, Pages

  Murray Brown, Fay ^a   Dorman, Saskie ^b  

^a Speciality Training Programme in Palliative Medicine   (United Kingdom)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; HALOPERIDOL; LORAZEPAM; PLACEBO; ANTIEMETIC AGENT; GEL;

ADVERSE OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NAUSEA AND VOMITING; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; GEL; NAUSEA; VOMITING;

ANTIEMETICS; DIPHENHYDRAMINE; GELS; HALOPERIDOL; HUMANS; LORAZEPAM; NAUSEA; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 84964695636     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006271.pub3     Document Type: Review

References (100)

1. Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ. A randomized trial of the effectiveness of eopical "ABH Gel" (Ativan®, Benadryl®, Haldol®) vs. placebo in cancer patients with nausea. Journal of Pain and Symptom Management 2014;48(5):797-803. [DOI: 10.1016/j.jpainsymman.2014.02.010]2836741
2. Abdelsayed G. Management of radiation-induced nausea and vomiting. Experimental Haematology 2007;35(4 Suppl):34-6. 2836743
3. Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea and vomiting: Results of two pilot trials. Journal of Supportive Oncology 2008;6(1):27-32. 2836745
4. Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM. Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. European Journal of Cancer 1991;27(5):561-5. 2836747
5. Buttner M, Walder B, von Elm E, Tramer MR. Is low-dose haloperidol a useful antiemetic? A meta-analysis of published and unpublished randomized trials. Anaesthesiology 2004;101:1454-63. 2836749
6. Casey C, Chen LM, Rabow MW. Symptom management in gynaecologic malignancies. Expert Review of Anticancer Therapy 2011;11(7):1077-89. 2836751
7. Cerchietti L, Navigante A, Sauri A, Palazzo F. Hypodermoclysis for control of dehydration in terminal-stage cancer. International Journal of Palliative Nursing 2000;6(8):370-4. 2836753
8. Cheung W, Zimmerman C. Pharmacologic management of cancer-related pain, dyspnoea and nausea. Seminars in Oncology 2011;38(3):450-9. 2836755
9. Chiu W. Update on antiemetics of chemotherapy. Journal of Internal Medicine of Taiwan 2007;18(6):342-9. 2836757
10. Chow C, Leung AK, Hon KL. Acute gastroenteritis: from guidelines to real life. Clinical and Experimental Gastroenterology 2010;3(1):97-112. 2836759
11. Christman RS, Weinstein RA, Larose JB. Low-dose haloperidol as antiemetic treatment in gastrointestinal disorders: a double-blind study. Current Therapeutic Research 1974;16(11):1171-5. 2836761
12. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiology Clinics of North America 2003;21:699-713. 2836763
13. Clary P, Lawson P. Pharmacologic pearls for end of life care. American Family Physician 2009;79(12):1059-65. 2836765
14. Cole DR, Duffy DF. Haloperidol for radiation sickness: control of associated nausea, vomiting, and anorexia. New York State Journal of Medicine 1974;74(9):1558-662. 2836767
15. Cole RM, Robinson F, Harvey L, Trethowan K, Murdoch B. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. Journal of Pain and Symptom Management 1994;9:48-50. 2836769
16. Davis M, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy of radiation. Journal of Pain and Symptom Management 2010;39(4):756-67. 2836771
17. De Vries PM. A double-blind cross-over clinical valuation of metoclopramide and a combination of haloperidol and isopropamide iodide in gastroenterology. Arzneimittel-Forschung 1969;19:1766-7. 2836773
18. DiVall M, Cervosimo R. Prevention and treatment of chemotherapy-induced nausea and vomiting. Formulary 2007;42(6):378-88. 2836775
19. Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2007;5:12-33. 2836777
20. Ettinger D, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, et al. Antiemesis. Journal of the National Comprehensive Cancer Network 2009;7(5):572-95. 2836779
21. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Annals of Oncology 2011;22(1):30-8. 2836781
22. Findlay M, Simes RJ, Cox K, Carmichael K, Chey T, McNeil E, et al. A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen. European Journal of Cancer 1993;29A(3):309-15. 2836783
23. Fischberg D. Randomised controlled trial of three antiemetics in the emergency department. Journal of Pain and Palliative Care Pharmacotherapy 2007;21(1):73-4. 2836785
24. Getto L, Zeserson E, Breyer M. Vomiting, diarrhoea, constipation and gastroenteritis. Emergency Medicine Clinics of North America 2011;29(2):211-37. 2836787
25. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supportive Care Cancer 2004;12:432-40. 2836789
26. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clinical Interventions in Ageing 2011;6(1):243-59. 2836791
27. Gonzales M, Widera E. Nausea and other nonpain symptoms in long-term care. Clinics in Geriatric Medicine 2011;27(2):213-28. 2836793
28. Grunberg SM, Gala KV, Lampenfeld M, Jamin D, Johnson K, Cariffe P, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. Journal of Clinical Oncology 1984;2(7):782-7. 2836795
29. Grunberg S, Clark-Snow RA, Koeller J. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Supportive Care in Cancer 2010;18 Suppl 1:S1-10. 2836797
30. Hardy J, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. Journal of Pain and Symptom Management 2010;40(1):111-6. 2836799
31. Herndon CM, Jackson IK, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002;22:240-50. 2836801
32. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nature Clinical Practice Oncology 2008;5(1):32-43. 2836803
33. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of anti-emetic drugs. Critical Reviews in Oncology/Hematology 2007;61(2):162-75. 2836805
34. Kohara H, Ueoka H, Takeyama H, Murakami T, Morita T. Sedation for terminally ill patients with cancer with uncontrollable physical distress. Journal of Palliative Medicine 2005;8(1):20-5. 2836807
35. Ladabaum U, Hasler WL. Novel approaches to the treatment of nausea and vomiting. Digestive Diseases 1999;17:125-32. 2836809
36. Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. Journal of Psychopharmacology 2010;24(11):1697-708. 2836811
37. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer Journal 2008;14(2):85-93. 2836813
38. McHugh M, Miller-Saultz D. Assessment of gastrointestinal symptoms in advanced illness. Primary Care - Clinics in Office Practice 2011;38(2):225-46. 2836815
39. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. Journal of Pain 2003;4(5):231-56. 2836817
40. Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. Journal of Pain and Symptom Management 2007;33(2):217-23. 2836819
41. Naeim A. Evidence-based recommendations for cancer nausea and vomiting. Journal of Clinical Oncology 2008;26(23):3903-10. 2836821
42. Navari M. Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncology 2007;4 Suppl 1:3-11. 2836823
43. Neidhart JA, Gagen M, Young DM, Wilson HE. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Cancer 1981;47:1439-43. 2836825
44. O'Connor B, Creedon B. Pharmacological treatment of bowel obstruction in cancer patients. Expert Opinion on Pharmacotherapy 2011;12(14):2205-14. 2836827
45. Owens NJ, Schauer AR, Nightingale CH, Golub GR, Martin RS, Williams HM, et al. Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis. Clinical Pharmacy 1984;3:167-70. 2836829
46. Perkins P, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006271.pub2]2836831
47. Pleuvry B. Physiology and pharmacology of nausea and vomiting. Anaesthesia and Intensive Care Medicine 2009;10(12):597-601. 2836833
48. Porreca F, Ossipov M. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: Mechanisms, implications and management options. Pain Medicine 2009;10(4):654-62. 2836835
49. Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Supportive Care in Cancer 2001;9:223-33. 2836837
50. Robbins EL, Nagel JD. Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. Journal of the American Geriatrics Society 1975;23:38-41. 2836839
51. Roeland E, Mitchell W, Elia G, Thornberry K, Herman H, Cain J, et al. Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: Physical symptoms. Journal of Supportive Oncology 2010;8(3):100-16. 2836841
52. Saller R, Hellenbrecht D. The benefit and risk of high dose metoclopramide in comparison to high dose haloperidol or trifluorpromazine in cisplatin-induced emesis. Klinische Wochenschrift 1985;63:428-32. 2836843
53. Siden H. Haloperidol as a palliative anti-emetic in a toddler: an evidence-base challenge. Journal of Pain and Symptom Management 2008;35(3):235-8. 2836845
54. Silvey L, Carpenter JT, Wheeler RH, Lee J, Conolley C. A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. Journal of Clinical Oncology 1988;6(9):1397-400. 2836847
55. Smith T, Ritter JK, Coyne PJ, Parker GL, Dodson P, Fletcher DS. Testing the cutaneous absorption of lorazepam, diphenhydramine and haloperidol gel (ABH gel) used for cancer-related nausea. Journal of Clinical Oncology 2011;29:Abstract 9021. 2836849
56. Smith T, Fletcher D, Coyne P, Dodson P, Parker G. ABH gel is not absorbed from the skin of normal volunteer so cannot be effective against nausea. Journal of Pain and Symptom Management. Conference: Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association. Denver, US, 2012. 2836851
57. Sperry M. A review of the 2006 ASCO antiemetic guidelines update. US Pharmacist 2007;32(1):22-8. 2836853
58. Stapleton J, Wo J. Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics. Gastrointestinal Endoscopy Clinics of North America 2009;19(1):57-72. 2836855
59. Tatum P. Haloperidol for nausea and vomiting. Journal of Pain and Palliative Care Pharmacotherapy 2009;23(4):426-7. 2836857
60. Tornetta FJ. Haloperidol as an antiemetic - guest discussion. Anesthesia and Analgesia - Current Researches 1971;50(6):1024-6. 2836859
61. Tornetta FJ. Double-blind evaluation of haloperidol for antiemetic activity. Anesthesia and analgesia. Current Researches 1972;51(6):964-7. 2836861
62. Trigg M, Inverso D. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplantation 2008;42(8):501-6. 2836863
63. Trigg M. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. Journal of Oncology Pharmacy Practice 2010;16(4):233-44. 2836865
64. Weschules DJ. Tolerability of the compound ABHR in hospice patients. Journal of Palliative Medicine 2005;8(6):1135-43. 2836867
65. White C, McPherson A, McCann MA, Sadler A, Fyvie J. Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic. Palliative Medicine 2006;20:215-6. 2836869
66. Hardy J, Yates P, Philip J, Martin P, Glare P, Currow D. A targeted versus empiric approach to antiemetic use in advanced cancer. In: MASCC/ISOO International Symposium on Supportive Care in Cancer. 26 June 2014. [http:/mascc2014.meetingxpert.net/MASCC_595/poster_96766/program.aspx/anchor96766]2836871
67. Yates P. The effectiveness of guideline driven antiemetic therapy versus single agent antiemetic therapy in patients with cancer and nausea not related to cancer therapy. Australian New Zealand Clinical Trials Registry 2010. [ACTRN12610000481077; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000481077]2836872
68. Hardy JR. A randomised, controlled, double blind study of oral methotrimeprazine versus oral haloperidol in patients with cancer and nausea not related to anticancer therapy (Nausea study 3), to compare the effectiveness of oral methotrimeprazine versus oral haloperidol in improving the management of nausea in patients with cancer and nausea not related to anticancer therapy. World Health Organization International Clinical Trials Registry Platform 23 February 2015. [ACTRN12615000177550; http://www.anzctr.org.au/ACTRN1261500077550.aspx]2836874
69. Barton MD, Libonati M, Cohen PJ. The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial. Anesthesiology 1975;42(4):508-12.
70. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting. Palliative Medicine 2001;15:247-53.
71. Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Latimer E, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. Journal of Pain and Symptom Management 2001;22:631-4.
72. Edmonds P, Karlsen S, Khan S, Addington-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliative Medicine 2001;15:287-95.
73. Egerton-Warburton D, Meek R, Mee MJ, Braitberg G. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. Annals of Emergency Medicine 2014;64(5):526-32.
74. Ewing G, Rogers M, Barclays S, McCabe J, Martin A, Todd C. Recruiting patients into a primary care based study of palliative care: why is it so difficult?. Palliative Medicine 2004;18:452-9.
75. Hardy JR. Placebo-controlled trials in palliative care: the argument for. Palliative Medicine 1997;11(5):415-8.
76. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
77. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003346]
78. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
79. Jordhoy M, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliative Medicine 1999;13:299-310.
80. Keeley P. Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clinical Evidence 2007;06:2406.
81. Kirkham SR, Abel J. Placebo-controlled trials in palliative care: the argument against. Palliative Medicine 1997;11(6):489-92.
82. Klinkenberg M, Willems DL, van der Wal G, Deeg DJH. Symptom burden in the last week of life. Journal of Pain and Symptom Management 2004;27:5-13.
83. Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 1996;78(10):2193-8.
84. Lindqvist O, Lundquist G, Dickman A, Bükki J, Lunder U, Hagelin CL, et al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. Journal of Palliative Medicine 2013;16(1):38-43.
85. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-32.
86. Mannix KA. Palliation of nausea and vomiting. Oxford Textbook of Palliative Medicine. Oxford University Press, 2004.
87. McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. Journal of Pain and Palliative Care Pharmacotherapy 2013;27(2):132-5.
88. Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration. Pharmacotherapy 2008;28(7):875-82.
89. Pereira J. Study comparing olanzapine with haloperidol for the relief of nausea and vomiting in patients with advanced cancer. clinicaltrials.gov. [ISRCTN58624349; NCT00124930; https://clinicaltrials.gov/ct2/show/NCT00124930?term=Haloperidol&rank=59]
90. Prommer E. Role of haloperidol in palliative medicine: an update. American Journal of Hospice and Palliative Medicine 2012;29(4):295-301.
91. Reuben DB, Mor V. Nausea and vomiting in terminal cancer patients. Archives of Internal Medicine 1986;146:2021-3.
92. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
93. Sanderson C, Hardy J, Spruyt O, Currow DC. Placebo and nocebo effects in randomized controlled trials: the implications for research and practice. Journal of Pain and Symptom Management 2013;46(5):722-30.
94. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
95. Smith HR, Cox LR, Smith BR. Dopamine receptor antagonists. Annals of Palliative Medicine 2012;1(2):137-42.
96. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. Journal of Pain and Symptom Management 2006;31(1):58-69.
97. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatric Quarterly 2001;72:325-36.
98. To TH, Agar M, Yates P, Currow DC. Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. Journal of Palliative Medicine 2014;17(9):1032-6.
99. Twycross R, Back I. Nausea and vomiting in advanced cancer. European Journal of Palliative Care 1998;5:39-45.
100. Twycross R, Wilcock A, Howard P. Palliative Care Formulary. 5th Edition. palliativedrugs.com, 2014.